NDAINJECTIONINJECTABLE
Approved
Jun 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THEELIN (estrone) is an injectable estrogen hormone replacement therapy approved in 1941 for menopausal and hypogonadal indications. It is a small-molecule steroid hormone that replaces or supplements endogenous estrogen production. The drug is administered via intramuscular or subcutaneous injection.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams should expect headcount optimization and focus shift toward legacy management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on THEELIN offers limited career growth due to its LOE-approaching lifecycle and minimal linked job openings. Roles on this product are primarily legacy/maintenance-focused with declining team size expectations.
Brand ManagerField Sales Representative
Worked on THEELIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.